Prof. Deby Vinski is a world-renowned authority in preventive, regenerative, and anti-aging medicine, celebrated for her groundbreaking work in stem cell therapy, genomic medicine, and biological age reversal. She is the Founder and President of the World Council of Preventive, Regenerative and Anti-Aging Medicine (WOCPM), an international body dedicated to advancing scientific innovation in longevity and cellular health. With a PhD in Stem Cell Science and a Master of Science in Anti-Aging Medicine, Prof. Vinski is also the Chairwoman of the Vinski Regenerative Center (VRC) in Jakarta and Monaco, the first Indonesian regenerative clinic officially registered in Europe. Her centers are recognized globally for their cutting-edge, personalized therapies in cellular regeneration, immune modulation, and disease prevention. Prof. Vinski has served as a Scientific Advisor to multiple international organizations, including collaborations with the European Society of Preventive, Regenerative and Anti-Aging Medicine (ESAAM) and is a certified Regenerative Medicine Clinical Consultant (RMCC–ASRM, USA). Her clinical and scientific contributions have positioned her at the forefront of global regenerative research and clinical application. In addition to her medical and scientific leadership, she is a prolific speaker and has been a plenary keynote presenter at international congresses hosted by the World Health Organization, UNESCO, and the American Academy of Anti-Aging Medicine (A4M). She has also been honored with numerous international awards, including recognition from global institutions for her outstanding leadership in advancing medical frontiers. Prof. Vinski is an advocate of the ethical, safe, and scientific use of stem cell technologies. Her pioneering work has made her a key figure in promoting medical tourism in Asia and Europe, making regenerative healthcare more accessible. She is also committed to public education, mentoring, and fostering the next generation of scientists and physicians in longevity science.

Dr. Y. James Kang is the Chief Scientist, Tasly Biopharmaceutical Company, Tianjin; Professor and Director of the Regenerative Medicine Research Center at Sichuan University West China Hospital; Director of Sichuan Regenerative Medicine Research and Technology Center; and Professor Emeritus, University of Louisville, Louisville, KY, USA. Dr. Kang received his Ph.D. in Toxicology and Cell Biology at Iowa State University in 1989 and completed postdoctoral training in Biochemistry and Molecular Biology at Cornell University Medical Center in 1991. He was Assistant Professor of Pharmacology and Toxicology, University of North Dakota School of Medicine (1991-1996); Associate Professor and University Scholar (1996-2001) and Professor and Distinguished University Scholar (2001-2017) in Medicine, Pharmacology and Toxicology, University of Louisville School of Medicine. He served several US-NIH study sections from 1997 to 2006, and other US federal agencies including USDA, US-EPA and US-Veterans Administrations from 1996 to 2005. He was an elected Fellow of the Academy of Toxicological Sciences since 2001, and he was the Editor-in-Chief of Cardiovascular Toxicology (2001-2022). His research interests are in regenerative medicine, focusing on MSCs, tissue injury signaling and organ rejuvenation. He made a major breakthrough in 3D bio-printing of stromal cell-based vascular graft for human implantation, leading the field of MSCs in organ rejuvenation.

Dr. Adel K. El-Naggar is a Professor and Section Chief of Head and Neck Pathology at the University of Texas M.D. Anderson Cancer Center. Dr. El-Naggar is the also the Director of the Head and Neck Pathology Fellowship. He received his M.D. degree from the Ein-Shams School of Medicine, Cairo, Egypt and research and pathology training at Vanderbilt and Case Western-Reserve University in Nashville and Cleveland, Ohio. Dr. El-Naggar is anEditor-in-Chief of the Head and Neck Oncology Journal and amember of several editorial boards of pathology, oncology and head and neck medical journals. He is also a member of national and international committees and cooperative groups in head and neck tumors. Dr. El-Naggar has authored and co-authored 610articles, 55 editorials and 10 book chapters on pathology of the head and neck. His main research efforts are focused onmolecular genetic characterization of head and neck and salivary carcinomas and biomarker integration in clinical management of patients with these tumors.

Dr. Mustafa Koroglu, MD, MSc is a visionary physician, health care strategist, and regenerative medicine pioneer. With a dynamic background as a military medical leader and CEO in prestigious health care organizations, he now leads LifeRegenera a cutting-edge platform focused on merging biotechnology, AI, and personalized medicine for healthy aging. His passion lies in translating scientific advancements into clinical practice, empowering individual stoextend both their health span and lifespan.

Dr. Cynthia N. Brysch is an award-winning life sciences executive with a distinguished career spanning over two decades. She is globally certified in Quality Assurance (QA) and Regulatory Affairs (RA) and serves as a highly regarded principal consultant in the industry. Her expertise encompasses domestic and international compliance frameworks, including GxP and ICH standards. With over 10 years of leadership experience as an ISO 13485/9001 accrediting authority, ICH committee member, FDA lead assessor, and recognized Key Opinion Leader (KOL), Dr. Brysch has played a pivotal role in shaping global regulatory standards and challenging industry norms. She has directed more than 500 product development campaigns, including initiatives in rare diseases and advanced therapies such as cell and gene therapies. Her notable achievements include securing marketing authorizations for 18 of the top 20 oncology combination products and contributing to the approval of the first CRISPR-Cas9 therapeutic. As a trusted principal consultant, Dr. Brysch has led comprehensive programs across the full product lifecycle—from early-stage research and non-clinical studies to clinical development and manufacturing. Her client portfolio ranges from innovative startups to established pharmaceutical, medical device, and biopharmaceutical companies. Renowned for her strategic insight and operational leadership, Dr. Brysch develops risk-based, data-driven compliance strategies that align scientific innovation with regulatory success. Her work continues to drive efficiency, strengthen stakeholder confidence, and support the successful commercialization of breakthrough medical products worldwide.

Dr Atul Dwivedi got his PhD from Zhengzhou university (World ranking :590, National ranking 47), China. He served as Assistant Professor, Associate Professor, and Visting Faculty in different universities of China. After completing MBBS degree from Zhengzhou university, he pursued three years Residency in orthopaedic Surgery from The first Affiliated Hospital of Zhengzhou university. He has been invited as a speaker in several international conferences. He sits as editorial board member / Advisory Board member/ reviewer in more than sixty renowned International Indexed Journals. He Authored and coauthored several research papers and book in indexed Journals. His several publication are indexed in semantic scholar, Google scholar, dimension data base and core collection of web of science (Clarivate Analytics), Index Copernicus, CNKI (China National Knowledge Infrastructure) Naver Academic (academic.naver.com), George M. Manuel Library, Carolina University (USA), (Malaysia), Majmaah University,Index Medicus, United States VHL (Virtual Health Library), Brazil. He coauthored and published a book in Germany, which is available on more than 20 online portals worldwide.